Class I obesity – focus on surgery
https://doi.org/10.17238/2072-3180-2022-1-9-20
Abstract
Te bariatric and metabolic surgery for patients with non-severe obesity is steel controversial. But now we have a current trend of expanding indications for this group all over the world. Based on the literature data of PubMed, Medline, Embase, ELIBRUARY, the possibility of developing obesity-associated diseases, as well as socio-psychological problems and a decrease in the quality of life in patients with initial obesity was analyzed. In addition, we analyzed efcacy and safety of bariatric procedures in patients with body mass index less than 35 kg/m2, including ones without metabolic disorders. Indications for surgery are suggested: 1) type 2 diabetes mellitus with insufcient effectiveness of glycemic control with hypoglycemic drugs or insulin and maintaining adequate pancreatic endocrine function; 2) progressive menstrual and fertility disorders as BMI increases; 3) abdomino-visceral form of obesity including without metabolic disorders in case of hereditary predisposition to their development; 4) psychological and social maladaptation, signifcantly reducing the quality of life (psychological rejection of excess weight, dysmorphophobia, bulimia) 5) insufcient effect or its absence from long-term (1 year) conservative treatment.
About the Authors
A. S. Tsepkovsky
S. M. Kirov Military Medical Academy (Moscow branch)
Russian Federation
Russian Federation
Tsepkovsky Alexander Sergeevich
Moscow, Russia, M.Cherkizovskaia 7, 107392
Y. I. Yashkov
The Center of Endosurgery and Lithotripsy
Russian Federation
Russian Federation
Yashkov Yuri Ivanovich – MD, PhD
Shosse Entusiastov, 62; Moscow,11112
V. V. Evdoshenko
Pirogov Russian National Research Medical University; Institute of Plastic Surgery and Cosmetology
Russian Federation
Russian Federation
Evdoshenko Vladimir Viktorovich – MD, PhD, Professor.
Moscow, Ostrovitianova 1, 117997
N. S. Bordan
Pirogov Russian National Research Medical University; Institute of Plastic Surgery and Cosmetology
Russian Federation
Russian Federation
Bordan Natalia Semenovna – Ph.D. in Medicine
Olhovskaia 27, Moscow, 105066
References
1. Dedov I.I., Mel’nichenko G.A., Shestakova M.V., Troshina E.A., Mazurina N.V., Shestakova E.A., Yashkov Yu.I., Neimark A.E., Biryukova E.V., Bondarenko I.Z., Bordan N.S., Dzgoeva F.H., Ershova E.V., Komshilova K.A., Mkrtumyan A.M., Petunina N.A., Romantsova T.I., Starostina E.G., Strongin L.G., Suplotova L.A., Fadeyev V.V. Russian national clinical recommendations for morbid obesity treatment in adults. 3rd revision (Morbid obesity treatment in adults). Obesity and metabolism, 2018, № 15(1), pp. 53–70. (In Russ.) https://doi.org/10.14341/omet2018153-70
2. Nakeshbandi M., Maini R., Daniel P., Rosengarten S., Parmar P., Wilson C., Kim J.M., Oommen A., Mecklenburg M., Salvani J., Joseph M.A., Breitman I. Te impact of obesity on COVID-19 complications: a retrospective cohort study. Int J Obes (Lond), 2020, № 44(9). https://doi.org/10.1038/s41366-020-0648-x
3. Fried M., Yumuk V., Oppert J.M., Scopinaro N., Torres A.J., Weiner R., Yashkov Y., Frühbeck G. European Association for the Study of Obesity; International Federation for the Surgery of Obesity – European Chapter. Interdisciplinary European Guidelines on metabolic and bariatric surgery. Obes Facts, 2013, № 6, pp. 49–68. https://doi.org/10.1159/000355480
4. NCD Risk Factor Collaboration. Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19,2 million participants. Lancet, 2016, April, № 2. https:// doi.org/10.1016/S0140-6736(16)30054-X
5. Smith K.B., Smith M.S. Obesity Statistics. Prim Care, 2016, № 1, рр. 21–35. https://doi.org/10.1016/j.pop.2015.10.001
6. Apovian CM. Obesity: Defnition, Comorbidities, Causes, and Burden. Am J Manag Care, 2016, № 22, pp. 176–185.
7. Bowman K., Atkins J.L., Delgado J., Kos K., Kuchel G.A., Ble A., Ferrucci L., Melzer D. Central adiposity and the overweight risk paradox in aging: follow-up of 130,473 UK Biobank participants. Am J Clin Nutr, 2017, № 1, рр. 130–135. https://doi.org/10.3945/ajcn.116.147157
8. Global BMI Mortality Collaboration. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet, 2016, Aug № 20. https://doi.org/10.1016/S0140-6736(16)30175-1
9. Heymsfeld S.B., Wadden T.A. Mechanisms, Pathophysiology, and Management of Obesity. Te New England Journal of Medicine. 2017, № 3, pp. 254–266. https://doi.org/10.1056/NEJMra1514009
10. Apovian C.M. Obesity: Defnition, Comorbidities, Causes, and Burden. Am J Manag Care, 2016, June № 2, published online. https://www.ajmc.com/view/obesity-defnition-comorbidities-causes-burden
11. Вaron M., Froguel P., Bonnefond A. Du nouveau dans la génétique des formes monogéniques d’obésité et son impact pour mieux en comprendre la physiopathologie [Something new in the genetics of monogenic obesity and its insights into pathophysiology]. Med Sci (Paris), 2020, № 10,pp. 859–865. French. https://doi.org/10.1051/medsci/2020156
12. Zhi C., Huang J., Wang J., Cao H., Bai Y., Guo J. Zhengquan S. Connection between gut microbiome and the development of obesity. European Journal of Clinical Microbiology & Infectious Diseases, 2019, Epub. Jul № 31. https://doi.org/10.1007/s10096-019-03623-x
13. Biddle S., García Bengoechea E, Pedisic Z. Screen Time, Other Sedentary Behaviours, and Obesity Risk in Adults: A Review of Reviews. Curr Obes Rep, 2017, № 2, pp. 134–147. https://doi.org/10.1007/s13679-017-0256-9
14. Campbell E., Franks A., Joseph P. Adolescent obesity in the past decade: A systematic review of genetics and determinants of food choice. J Am Assoc Nurse Pract, 2019, № 6, pp. 344–351. https://doi.org/10.1097/JXX.0000000000000154
15. Kershaw E.E., Flier J.S. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab, 2004, № 89, I 6, pp. 2548–2556. https://doi.org/10.1210/jc.2004-0395
16. Kadowaki T., Yamauchi T., Kubota N., et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. Te Journal of Clinical Investigation, 2006, № 7, pp. 1784–1792. https://doi.org/10.1172/JCI29126
17. Bastard J., Maachi M., Lagathu C., et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw, 2006, № 17(1), pp. 4–12.
18. Ametov A.S., Tertychnaya E.A. Insulin resistance and lipotoxicity are two facets of the same problem in type 2 diabetes mellitus and obesity. Endocrinology: news, opinions, training, 2019. № 2 (27). C. 25–33. https://doi.org/10.24411/2304-9529-2019-12003;
19. Ruyatkina L.A., Ruyatkin D.S. Obesity: "crossroads" of opinions, knowledge and opportunities. Medical Advice, 2020. № 7. С. 108–120.https://doi.org/10.21518/2079-701X-2020-7-108-120
20. Longo M., Zatterale F., Naderi J., Parrillo L., Formisano P., Raciti G.A. et al. Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metabolic Complications. International Journal Molecular Sciences, 2019, № 20(9), pp. 23–58. https://doi.org/10.3390/ijms20092358
21. Misra A., Jayawardena R., Anoop S. Obesity in South Asia: Phenotype, Morbidities, and Mitigation. Current Obesity Reports, 2019, № 8(1), pp. 43–52. https://doi.org/10.1007/s13679-019-0328-0
22. Kalra D., Vijayaraghavan K., Sikand G., Desai N.R., Joshi P.H., Mehta A., Karmally W., Vani A., Sitafalwalla S.J., Puri R., Duell P.B., Brown A. Prevention of atherosclerotic cardiovascular disease in South Asians in the US: A clinical perspective from the National Lipid Association. Journal of Clinical Lipidology, 2021, № 15(3), pp. 402–422. https://doi.org/10.1016/j.jacl.2021.03.007
23. Williams R., Periasamy M. Genetic and Environmental Factors Contributing to Visceral Adiposity in Asian Populations. Endocrinology and Metabolism, 2020, № 35(4), Epub. https://doi.org/10.3803/EnM.2020.772
24. Huang Y.M., Lin Y.K., Lee W.J., Hur K.Y., Kasama K., Cheng A.K.S., Lee M.H., Wong S.K., Soong T.C., Lee K.T., Lomanto D., Lakdawala M., Su Y.H., Wang W. Long-term outcomes of metabolic surgery in overweight and obese patients with type 2 diabetes in Asia. Diabetes Obesity and Metabolism, 2021, № 23(3), pp. 742–753. https://doi.org/10.1111/dom.14279
25. Babenko V., Babenko R., Gamieldien J., Markel A. FTO haplotyping underlines high obesity risk for European populations. BMC Med Genomics, 2019, № 12(2), Epub. https://doi.org/10.1186/s12920-019-0491-x
26. Dedov I.I., Shestakova M.V., Melnichenko G.A., Mazurina N.V., Andreeva E.N., Bondarenko I.Z., Gusova Z.R., Dzgoeva F.K., Eliseev M.S., Ershova E.V., Zhuravleva M.V., Zakharchuk T.A., Isakov V.A., Klepikova M.V., Komshilova K.A., Krysanova V.S., Nedogoda S.V., Novikova A.M., Ostroumova O.D., Pereverzev A.P., Rozhivanov R.V., Romantsova T.I., Ruyatkina L.A., Salasyuk A.S., Sasunova A.N., Smetanina S.A., Starodubova A.V., Suplotova L.A., Tkacheva O.N., Troshina E.A., Khamoshina M.V., Chechelnitskaya S.M., Shestakova E.A., Sheremet’eva E.V. Interdisciplinary clinical practice guidelines “management of obesity and its comorbidities. Obesity and metabolism, 2021, № 18(1), pp. 5–99. (In Russ.) https://doi.org/10.14341/omet12714
27. Andreeva E.N., Sheremetyeva E.V., Fursenko V.A. Obesity – threat to the reproductive potential of Russia. Obesity and metabolism. 2019, № 16(3), pp. 20-28. (In Russ.) https://doi.org/10.14341/omet10340
28. Smith G.I., Mittendorfer B., Klein S. Metabolically healthy obesity:facts and fantasies. Te Journal of Clinical Investigation, 2019, № 129(10), pp. 3978–3989. https://doi.org/10.1172/JCI129186
29. Liu C., Wang C., Guan S., Liu H., Wu X., Zhang Z. et al. Te Prevalence of Metabolically Healthy and Unhealthy Obesity according to Different Criteria. Obesity Facts, 2019, №12(1), pp. 78–90. https://doi.org/10.1159/000495852
30. Vliet-Ostaptchouk J., Nuotio M., Slagter S.N., Doiron D., Fischer K., Foco L., Gaye A., Gögele M., Heier M., Hiekkalinna T., Joensuu A., Newby C., Pang C., Partinen E., Reischl E., Schwienbacher C., Tammesoo M., Swertz M.A., Burton P., Ferretti V., Fortier I., Giepmans L., Harris J.R, Hillege H.L., Holmen J., Jula A., Kootstra-Ros J.E., Kvaløy K., Holmen T.L., Männistö S., Metspalu A., Midthjell K., Murtagh M.J., Peters A., Pramstaller P.P., Saaristo T., Veikko S., Stolk R.P., Uusitupa M., Harst P., M ., Klauw M., Waldenberger M., Perola M., Wolffenbuttel B. Te prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC Endocrine Disorders, 2014, № 14(1), Epub. https://doi.org/10.1186/1472-6823-14-9
31. Garvey W., Garber A., Mechanick J. et al. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the 2014 Advanced Framework for a New Diagnosis of Obesity as a Chronic Disease. Endocrine Practice, 2014, № 20(9), pp. 77–89. https://doi.org/10.4158/EP14280.PS
32. Bray G.A., Ryan D.H. Evidence-based weight loss interventions: Individualized treatment options to maximize patient outcomes. Diabetes Obesity and Metabolism, 2021, № 23 (S1), pp. 50–62. https://doi.org/10.1111/dom.14200
33. Lobykina E.N. Patients weight-reducing treatment in health centers: choice of methods and estimation of efciency. Journal for Continuing Medical Education, 2014, № 2, pp. 38–40. (In Russ.)
34. Hainer V., Toplak H., Mitrakou A. Treatment modalities of obesity: What fts whom? Diabetes Care, 2008, №2(2), pp. 269–277. https://doi. org/10.2337/dc08-s265
35. Dedov II., Mokrysheva N.G., Mel’nichenko G.A., Troshina E.A., Mazurina N.V., Ershova E.V., Komshilova K.A., Andreeva E.N., Antsiferov M.B., Biriukova E.V., Bordan N.S., Vagapova G.R., Volkova A.R., Volkova N.I., Volynkina A.P., Dzgoeva F.Kh., Kiseleva T.P., Neimark A.E., Romantsova T.I., Ruiatkina L.A., Suplotova L.A., Khalimov Iu.Sh., Yashkov Iu.I. Obesity. Clinical guidelines. Consilium Medicum, 2021, № 23(4), pp. 311–325. (In Russ.) https://doi.org/10.26442/20751753.2021.4.200832
36. Gastrointestinal Surgery for Severe Obesity 25—27 March 1991. Obesity Surgery, 1991, № 1(3), pp. 257–265. https://doi.org/10.1381/096089291765560962
37. Statement on Patient Selection for Bariatric Surgery. Obesity Surgery, 1997, № 7(1), pp. 41–41. https://doi.org/10.1381/096089297765556259
38. Clinical guidelines on the identifcation, evaluation, and treatment of overweight and obesity in adults: executive summary. Expert Panel on the Identifcation, Evaluation, and Treatment of Overweight in Adults. The American Journal of Clinical Nutrition, 1998, № 68(4), pp. 899–917. https://doi.org/10.1093/ajcn/68.4.899
39. P000008/S017: FDA Summary of Safety and Effectiveness Data 2011. https://www.accessdata.fda.gov/cdrh_docs/pdf/P000008S017b.pdf
40. Busetto L, Dixon J, De Luca M, Shikora S, Pories W, Angrisani L. Bariatric surgery in class I obesity: a Position Statement from the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO). Obes Surg., 2014, № 24(4), pp. 487–519. https://doi.org/10.1007/s11695-014-1214-1
41. Yashkov Y., Lutsevich O., Bordan N. Sleeve Gastrectomy in patients with BMI <35. European Obesity Summit (EOS) - Joint Congress of EASO and IFSO-EC, Gothenburg, Sweden, June 1–4, 2016: Abstracts. Obes Facts, 2016, № 9(S1), p 376. https://doi.org/10.1159/000446744
42. Te IFSO Global Registry Report 2019. https://www.ifso.com/pdf/5th-ifso-global-registry-report-september-2019
43. Russian national bariatric registry. (In Russ.) https://bareoreg.ru/
44. Troshina E.A., Ershova E.V. Pharmacotherapy of obesity: what’s new? Problems of Endocrinology, 2018, № 64(4), pp. 270–276. (In Russ.) https://doi.org/10.14341/probl9315
45. Colquitt J.L., Pickett K., Loveman E., Frampton G.K. Surgery for weight loss in adults. Cochrane Database Syst Rev, 2014. https://doi.org/10.1002/14651858.CD003641.pub4
46. Yashkov Y.I., Lutsevich O.E., Bordan N.S., Ivleva O.V. Efciency of laparoscopic sleeve gastrectomy in patients with obesity. Obesity and metabolism, 2015, № 12(1), pp. 20–28. (In Russ) https://doi.org/10.14341/OMET2015120-28
47. Amin A., Siddiq G., Haider M. I., Choudry U. K., Izza Nazir. Laparoscopic Sleeve Gastrectomy versus Lifestyle Modifcation in Class I Obesity in Pakistani Population: A Prospective Cohort Study. Cureus, 2019, № 11(6), Epub. https://doi.org/10.7759/cureus.5031
48. GroverB.T., Morell M.C., Kothari S.N. Defning Weight Loss Afer Bariatric Surgery: a Call for Standardization. Obes Surg., 2019, № 29(11), pp. 3493–3499. https://doi.org/10.1007/s11695-019-04022-z
49. Vitiello A., Angrisani L., Santonicola A., Iovino P., Pilone V., Forestieri P. Bariatric Surgery Versus Lifestyle Intervention in Class I Obesity: 7–10-Year Results of a Retrospective Study. World J Surg, 2019, № 43(3), pp. 758–762. https://doi.org/10.1007/s00268-018-4847-8
50. Seki Y., Kasama K., Kikkawa E., Yokoyama R., Nabekura T., Sano A., Amiki M., Kurokawa Y. Five-Year Outcomes of Laparoscopic Sleeve Gastrectomy in Japanese Patients with Class I Obesity. Obes Surg., 2020, № 11, pp. 4366–4374. https://doi.org/10.1007/s11695-020-04789-6
51. Yashkov Y., Lutsevich O., Bordan N., Bekuzarov D., Malykhina A.. Results of laparoscopic Sleeve Gastrectomy in patients with preoperative BMI less than 35 kg/m2. 2-nd IFSO-EC Symposium 2-4 May 2019, Lyon, France. Book of abstracts, 2019, p. 24.
52. Feng X., Andalib A., Brethauer S. A., Schauer P.R., Aminian A. How safe is bariatric surgery in patients with class I obesity (body mass index 30-35 kg/m2)? Surg Obes Relat, 2019, № 2, pp. 253–260. https://doi.org/10.1016/j.soard.2018.12.006
53. Koffman B.M., Greenfeld L.J., Ali II., Pirzada N.A. Neurologic complications afer surgery for obesity. Muscle and Nerve, 2006, № 33(2), pp. 166–176. https://doi.org/10.1002/mus.20394
54. Volkova A.R., Semikova G.V., Dygun O.D. et al. Practical recommendations of the obesity management task force of the European Association for the Study of Obesity for the post-bariatric surgery medical management (2017) in clinical use. Consilium Medicum, 2020, № 22(4), pp. 36–42. (In Russ.) https://doi.org/10.26442/20751753.2020.4.200114
55. Tai K., Yeung 1 D., Penney N., Ashrafan L., Darzi A., Ashrafan H. Does sleeve gastrectomy expose the distal esophagus to severe reflux? A Systematic Review and Meta-analysis. Annals of Surgery Volume XX, 2020, № 20, pp. 257–265. https://doi.org/10.1097/SLA.0000000000003275
56. Sudlow A. C., Roux C. W., Pournaras D.J. Review of Advances in Anti-obesity Pharmacotherapy: Implications for a Multimodal Treatment Approach with Metabolic Surgery. Obes Surg., 2019, № 12, pp. 4095–4104. https://doi.org/10.1007/s11695-019-04206-7
Review
For citations:
Tsepkovsky A.S., Yashkov Y.I., Evdoshenko V.V., Bordan N.S. Class I obesity – focus on surgery. Moscow Surgical Journal. 2022;(1):9-20. (In Russ.) https://doi.org/10.17238/2072-3180-2022-1-9-20
Views:
367
Email this article 